Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough

Next Previous
Trial Profile

A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Sponsors Afferent Pharmaceuticals

Most Recent Events

  • 20 May 2020 Results assessing difference in cough frequency and patient-assessment of cough severity, presented at the 116th International Conference of the American Thoracic Society.
  • 16 Mar 2020 Results evaluating comorbid conditions and secondary diagnoses associated with cough using two phase II trials (NCT02349425 and NCT02612610) presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 25 Feb 2019 Results of post-hoc analysis assessing proportion of responders in terms of cough trigger presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top